SecBot SecBot
SECBOTREPLAY Home › Report › NRXP

NRXP · Contested proxy election

NRX Pharmaceuticals, Inc. · DEF 14A filed Nov 5, 2026 at 16:30 ET

At the news

NEUTRALIMPACT 4/10

DEF 14A filed Nov 5, 2026 at 16:30 ET

NRX Pharmaceuticals filed its definitive proxy statement for the 2026 annual meeting, seeking to elect Dennis McBride as the sole Class II director and ratify Weinberg & Company as auditors. The filing is routine but occurs alongside a DEFA14A filed the same day indicating a contested election, adding governance uncertainty.

  • Annual meeting scheduled for December 17, 2026, virtual-only format.
  • Only one director nominee: Dennis McBride for Class II.
  • Board has 5 directors, all male, all White; classified board with staggered three-year terms.
  • CEO Jonathan Javitt also serves as Chairman (combined role).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access